Lysosomal membrane and associated components

The lysosomal membrane is a specialized phospholipid bilayer that serves as a protective barrier, sequestering acidic hydrolases from the cytoplasm while facilitating controlled degradation and recycling of macromolecules (Saftig & Klumperman, 2009, Nature Reviews Molecular Cell Biology). It is characterized by a high concentration of integral membrane proteins, most notably Lysosomal-associated membrane proteins 1 and 2 (LAMP1/2), which form a protective glycocalyx, and the vacuolar H+-ATPase (V-ATPase) that maintains the acidic luminal pH (Mindell, 2012, Annual Review of Physiology). Beyond degradation, the membrane acts as a signaling hub for nutrient sensing via the mTORC1 pathway and regulates ion homeostasis through various transporters like NPC1 and cystinosin (Settembre et al., 2013, Nature Reviews Genetics). In pathological states, such as lysosomal storage diseases, defects in these components lead to toxic substrate accumulation, whereas in cancer, the membrane may be targeted to induce lysosomal membrane permeabilization (LMP) and subsequent cell death (Boya & Kroemer, 2008, Nature Reviews Drug Discovery). Therapeutic interventions include lysosomotropic agents like hydroxychloroquine, which accumulate in the lumen to inhibit autophagy, and enzyme replacement therapies that are trafficked to this compartment to restore metabolic function (Appelqvist et al., 2013, Journal of Molecular Cell Biology).

Other names

Lysosomal membraneLysosomal limiting membraneLysosomal compartmentLysosomal surface

Drugs targeting lysosomal components act through several mechanisms: lysosomotropic accumulation leading to increased luminal pH and inhibition of acid hydrolases; enzyme replacement therapy (ERT) where recombinant enzymes are delivered to the lysosome; substrate reduction therapy (SRT) to decrease the burden on lysosomal degradation; pharmacological chaperones that stabilize mutant enzymes; and the induction of lysosomal membrane permeabilization (LMP) to release cathepsins and trigger apoptosis in cancer cells (Boya & Kroemer, 2008, Nature Reviews Drug Discovery; Appelqvist et al., 2013, Journal of Molecular Cell Biology).